Breast cancer is a highly heterogeneous disease, with several different subtypes being characterized by distinct histology, gene expression patterns, and genetic alterations. The tumor suppressor gene retinoblastoma 1 (RB1) is frequently lost in both luminal-B and triple-negative tumor (TNT; i.e., estrogen receptor–, progesterone receptor–, and human epidermal growth factor receptor 2–negative) breast cancer subtypes. However, a causal role for RB1 loss in different subtypes remains undefined. Here we report that deletion of Rb alone or together with its relative p107 in mouse mammary stem/bipotent progenitor cells induced focal acinar hyperplasia with squamous metaplasia. These lesions progressed into histologically diverse, transplantable...
Breast cancer is the most common tumor among women with inherited mutations in the p53 gene (Li-Frau...
Understanding the mechanisms underlying tumour heterogeneity is key to the development of treatments...
Approximately 70 % of human breast cancers are estrogen receptor! (ER!)-positive, but the origins of...
Breast cancer is a highly heterogeneous disease, with several different subtypes being characterized...
Breast cancers that are triple-negative for the clinical markers ESR1, PGR, and HER2 typically bel...
Triple negative breast cancer (TNBC) is characterized by multiple genetic events occurring in concer...
The retinoblastoma tumor suppressor (RB) protein is functionally inactivated in the majority of huma...
Mutation and loss of function in p53 are common features among human breast cancers. Here we use BAL...
Mutation and loss of function in p53 are common features among human breast cancers. Here we use BAL...
<div><p>Breast cancers that are “triple-negative” for the clinical markers ESR1, PGR, and HER2 typic...
Introduction Breast cancers can be classified using whole genome expression into distinct subtypes t...
While previous studies using genetically engineered mice (GEM) have indicated potential effects of s...
Alterations in p53 and Rb tumor suppressors or their pathways are common in human breast cancer. We ...
Targeted therapies against basal-like breast tumors, which are typically ‘triple-negative breast can...
Breast cancer is the most common tumor among women with inherited mutations in the p53 gene (Li-Frau...
Breast cancer is the most common tumor among women with inherited mutations in the p53 gene (Li-Frau...
Understanding the mechanisms underlying tumour heterogeneity is key to the development of treatments...
Approximately 70 % of human breast cancers are estrogen receptor! (ER!)-positive, but the origins of...
Breast cancer is a highly heterogeneous disease, with several different subtypes being characterized...
Breast cancers that are triple-negative for the clinical markers ESR1, PGR, and HER2 typically bel...
Triple negative breast cancer (TNBC) is characterized by multiple genetic events occurring in concer...
The retinoblastoma tumor suppressor (RB) protein is functionally inactivated in the majority of huma...
Mutation and loss of function in p53 are common features among human breast cancers. Here we use BAL...
Mutation and loss of function in p53 are common features among human breast cancers. Here we use BAL...
<div><p>Breast cancers that are “triple-negative” for the clinical markers ESR1, PGR, and HER2 typic...
Introduction Breast cancers can be classified using whole genome expression into distinct subtypes t...
While previous studies using genetically engineered mice (GEM) have indicated potential effects of s...
Alterations in p53 and Rb tumor suppressors or their pathways are common in human breast cancer. We ...
Targeted therapies against basal-like breast tumors, which are typically ‘triple-negative breast can...
Breast cancer is the most common tumor among women with inherited mutations in the p53 gene (Li-Frau...
Breast cancer is the most common tumor among women with inherited mutations in the p53 gene (Li-Frau...
Understanding the mechanisms underlying tumour heterogeneity is key to the development of treatments...
Approximately 70 % of human breast cancers are estrogen receptor! (ER!)-positive, but the origins of...